CSIMarket
 
Organon and Co   (OGN)
Other Ticker:  
 
 
Price: $17.8100 $-0.47 -2.571%
Day's High: $18.31 Week Perf: -2.52 %
Day's Low: $ 18.06 30 Day Perf: -4.35 %
Volume (M): 67 52 Wk High: $ 24.79
Volume (M$): $ 1,215 52 Wk Avg: $18.50
Open: $18.06 52 Wk Low: $10.84



 Market Capitalization (Millions $) 4,566
 Shares Outstanding (Millions) 256
 Employees 9,300
 Revenues (TTM) (Millions $) 6,263
 Net Income (TTM) (Millions $) 1,023
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 253

Organon And Co
Organon and Co is a pharmaceutical company that was founded nearly a century and a half ago in the Netherlands. It has since grown into a global biopharmaceutical company that specializes in developing and manufacturing innovative medicines to improve patients' lives.

The company's name, Organon, refers to the Greek word "organon," which means "tool" or "instrument." This reflects Organon's mission to create tools and solutions to help physicians and healthcare providers feel confident in their treatment decisions.

Organon and Co's focus is on three main areas: Women's Health, Biosimilars, and Established Brands. The Women's Health division focuses on developing and providing solutions for women's health and wellness, including contraception, infertility, and menopause treatments. The Biosimilars division aims to provide access to high-quality, affordable biosimilars, helping to increase patient access to life-saving biologic medicines. The Established Brands division focuses on providing innovative solutions to improve the health and well-being of patients, including treatments for cardiovascular disease, migraine, and schizophrenia.

Organon and Co is committed to advancing science and research to better understand and meet patients' needs. They invest heavily in research and development, focusing on developing innovative medicines and treatments using state-of-the-art technologies.

In addition to its focus on innovative research and development, Organon and Co is committed to social responsibility and sustainability. They have created programs and initiatives to promote health and wellness in underserved communities, reduce their environmental impact, and improve patient access to medicines.

Overall, Organon and Co's mission is to improve patients' lives by providing innovative solutions and treatments that address pressing medical needs. They are committed to advancing science and research, promoting social responsibility, and ensuring patient access to life-saving medicines.


   Company Address: 30 Hudson Street, Floor 33 Jersey City 7302 NJ
   Company Phone Number: 430-6900   Stock Exchange / Ticker: NYSE OGN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Organon And Co

Rapid Revenue Growth Fueled by $442M Boost in Income Tax Provisions

In a recent news development, pharmaceutical giants Organon and Eli Lilly have announced a strategic partnership aimed at revolutionizing the migraine medication market in Europe. Organon, known for its focus on women's health, will now become the exclusive distributor and promoter of two premium migraine medicines - Emgality (Galcanezumab) and RAYVOW (Lasmiditan) across the region.
This collaboration comes at a crucial time for Organon as the company faces declining revenues. In the third quarter of 2023, Organon reported a year-on-year revenue decrease of 1.17%, reflecting the challenging commercial landscape in the pharmaceutical industry. This decline was potentially faster than that experienced by its competitors. However, it is worth noting that Organon maintained a positive net margin of 3.82%, indicating its ability to generate a profit after covering all costs.

Product Service News

Organon Seizes Sole Europen Distribution Rights for Lilly's Migraine Medications: A Lifesaver against Declining Profits?

Published Tue, Dec 19 2023 2:26 AM UTC


Organon and Eli Lilly Forge Strategic Partnership for Migraine Medications in Europe Amidst Competitive Revenue Declines
The pharmaceutical giants Organon (NYSE: OGN) and Eli Lilly and Company (Lilly) have announced a strategic agreement, placing Organon as the exclusive distributor and promoter of two premium migraine medicines, Emgality (Galcanezumab) and RAYVOW (...

Contract

Navigating the Competitive Landscape: A Closer Look at Organon's Q3 2023 Performance and Strategies to Outshine in Life Science Industry

Published Mon, Dec 18 2023 6:19 PM UTC


In the third quarter of 2023, amid a complex market backdrop, global life science company Organon (NYSE: OGN) reported a year-on-year revenue decrease of -1.17%. Despite this decline, Organon appears to be holding up well compared to its competitors, which recorded the same decrease in earnings during the same quarter.
A closer look at the financials reveals a sign...

Product Service News

Samsung Bioepis and Organon Achieve FDA Milestone For Biosimilar Interchangeability Designation, Shaping the Future of Affordable Healthcare

Published Tue, Nov 7 2023 9:16 PM UTC

Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application for Biosimilar Interchangeability Designation, Marking a Milestone in Healthcare Innovation
INCHEON, South Korea and JERSEY CITY, N.J., Nov. 07, 2023 - In a significant development for the pharmaceutical industry, Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) have an...

Organon And Co

Organon And Co, a Prominent Pharmaceutical Company, Suffers Slender Top-Line Decline in Fiscal Year Ending Sep 30, 2023

Organon And Co, a leading company in the industry, recently released its financial results for the fiscal span ending September 30, 2023. The company reported a significant reduction in earnings per share (EPS) by -74.16% to $0.23 compared to the previous year. Additionally, its revenue decreased by -1.171% to $1.52 billion year on year.
Compared to the preceding reporting season, Organon And Co experienced a decline in EPS from $0.95 per share and a decrease in revenue by -5.535% from $1.61 billion. This indicates a challenging period for the company in terms of profitability and financial performance.






 

Organon And Co's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Organon And Co does not provide revenue guidance.

Earnings Outlook
Organon and Co does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com